Market reporting

#BioIndustry Association #Biotech #Investment #Market reporting #UK

Buoyant UK biotech sector secures £1.8bn investment in 2023

The UK’s life sciences and biotech sector showed resilience in 2023, securing £1.8 ($2.2) billion in equity investment despite a challenging global economic climate, according to a report by the UK BioIndustry Association (BIA). This follows another BIA report in January 2024, which showed that the UK is a global… Read More

#Business & Investment #News

European map
#Advanced Therapies Europe #Biologics / Biotechnology #Cancer immunotherapy #CAR-T #Cell and gene therapy #Cell therapy #Collaboration #Europe #Immuno-oncology #Market reporting #Oncology #Start-ups

New podcast: Why is Europe a drug discovery epicentre?

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: European drug discovery and development success stories,… Read More

#News

Market growth 2024
#Biotech #Funding #GlobalData #Investment #Market reporting

Biotech funding recovery predicted for 2024

The biotech market is heading to recovery in 2024, following a marked downturn in investment in 2022 and 2023, according to healthcare industry professionals. A GlobalData survey ‘The State of the Biopharmaceutical Industry 2024’ found that more than 40% of the healthcare industry professionals surveyed globally expressed an optimistic or… Read More

#Business & Investment #News #Trending News

#Biopharmaceuticals #Clarivate #Drug development #Drug discovery #Market reporting

Thirteen potential blockbuster drugs to watch in 2024

Thirteen new-to-market therapeutics and drugs poised to launch in 2024 will achieve ‘blockbuster’ status by 2029 or deliver game-changing benefits to patients. They include therapeutics for conditions including breast cancer, haemophilia A, sickle cell disease, Crohn’s disease, ulcerative colitis, respiratory syncytial virus (RSV) and multiple myeloma, among others. The predictions were… Read More

#News #Trending News #Trends & Analysis

#Biologics #GlobalData #Inflammatory Bowel Disease #Market reporting #Small molecules

Biologics for bowel disease face threat from cheaper small molecules

The total sales of inflammatory bowel disease (IBD) drugs are estimated to reach approximately $10.2 billion in the US in 2023, according to analysts. The increase in IBD biologic treatments has been a major driving force in the growth of this market in recent years. In 2007, AbbVie’s Humira received… Read More

#Market Reports #News

#Drug development #Drug discovery #Life science #Life sciences #Market reporting #TechBio #UK

‘Life Sciences Future50’ shines light on UK innovation

PwC has published a new report on the UK life sciences industry ‘The Life Sciences Future50’, highlighting companies that illustrate world-class science and innovation, including 32 in the therapeutics space. According to the report, the life science industry represents a £43.4 ($52.7) billion annual contribution to GVA and supports 646,000… Read More

#News #Trending News #Trends & Analysis

Molecule concept biology
#Biomarkers #Drug discovery #Market reporting #Spatial biology

DDW Fall issue out now

The Fall issue of Drug Discovery World (DDW) is out now featuring expertise on what spatial biology tells us about drug discovery and disease. Read the digital version free here. Other features in the Fall issue include: How biomarkers can help discover new treatments for women’s health A market report… Read More

#News

#Biotech #Cell and gene therapy #Clinical trials #Market reporting #Oncology

New podcast: A deep dive into US drug discovery

This is the latest episode of the free DDW narrated podcast, “What lies in the future for genomics and big data?”, which covers two articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “US biotech: Focus on positive growth… Read More

#News

#Big pharma #Biopharmaceuticals #Market reporting #Norstella

Biopharma will be worth $1.6tn in 2028, analysts predict

A new forecast predicts global prescription drug sales to be worth $1.6tn by 2028. Global biopharmaceutical revenues are forecast to grow at a compounded annual rate of 5.9% to 2028, according to the latest World Preview report published by Evaluate. The annual report forecasts that while the industry will have… Read More

#Business & Investment #Market Reports #News #Trends & Analysis

#Bloomberg Intelligence #Business #Market reporting #Obesity

Market analysts predict $44 billion in obesity drug sales in 2030

Sales of branded anti-obesity drugs (AOB) could hit $44 billion in 2030 vs $2.5 billion in 2022, with just under 70% stemming from the US. The predictions come from analysts at Bloomberg Intelligence (BI), who believe securing broad reimbursement and supply are key, with a possible upside from further innovations… Read More

#Business & Investment #News #Trends & Analysis

Cell and gene therapy
#Advanced Therapy Medicinal Products (ATMPs) #Cell and gene therapy #Guide #Market reporting

Expert view: What’s next for cell and gene therapy?

Listen to this article on the DDW Podcast: What are the global innovations in cell and gene therapy? What opportunities and challenges are emerging and can therapies get to market faster? DDW's Megan Thomas finds out. Skills gap Bruce Levine, International Society for Cell & Gene Therapy (ISCT) Immediate Past President… Read More

#Exclusive Content #Trends & Analysis

#Biosimilars #IQVIA #Market reporting #United States

US drugs market grows by 5% in 2022

The US market for medicines grew by 5% in 2022, reaching a total value of $429Bn on a net price basis. This was driven by a range of factors, including an increase in health services utilisation, which is now back to pre-pandemic levels, and the entry of new medicines into… Read More

#Editor's Choice #Market Reports #News

Map of the United States
#Biologics / Biotechnology #Biotech hubs #Life sciences #Market reporting #United States

Where are the hottest drug discovery hubs in the US?

Listen to this article on the DDW Podcast: DDW's Megan Thomas takes a snapshot of the US biotech market and some of the ongoing research coming out of the US. In 2021, Savills put together a report on the regional hubs attracting science/pharma investment1. The report notes that the focus on science… Read More

#Exclusive Content #Market Reports

Scandinavia
#Drug development #Drug discovery #Life sciences #Market reporting #Scandinavia #Sweden

Scandinavia: insight into opportunities for drug discovery

DDW Editor Reece Armstrong explores the Scandinavian drug discovery sector and speaks to key players about Sweden’s place in the market. Scandinavia represents one of the most exciting but perhaps underrepresented markets for the discovery and development of pharmaceuticals. Though not without its challenges, the life sciences industry in Scandinavia… Read More

#Exclusive Content #Market Reports

#Biopharmaceuticals #GlobalData #Market reporting #Pharmaceutical industry

Top 20 global biopharma companies report 5.4% growth

The top 20 biopharmaceutical companies have recorded a growth of 5.4% in aggregate market capitalisation – from $3.43 trillion on December 31, 2021 to $3.61 trillion on December 31, 2022.  According to analytics company GlobalData, 11 companies indicated double-digit growth, with four companies – Merck & Co (45.3%), Vertex Pharmaceuticals… Read More

#Business & Investment #Editor's Choice #Market Reports #News